Teva Pharmaceutical Industries Limited (TEVA) Stock Forecast
TEVA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.54 / 5 from 13 analysts
- Price target
- $47.58 average of analyst targets
- Upside to target
- +14.7% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.70
- 52-week range
- $18.95 – $41.50
TEVA analyst ratings
13 analystsNumber of analysts at each rating.
TEVA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TEVA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.73 | $0.60 | $0.89 | $0.78 | −9.9% | 10 |
| Current fiscal year (2026) | $2.11 | $1.91 | $2.94 | $2.93 | −29.5% | 13 |
| Next fiscal year (2027) | $3.08 | $2.86 | $3.35 | $2.11 | +46.4% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TEVA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $4.24B | $4.04B | $4.38B | −5.4% | 11 |
| Current fiscal year (2026) | $16.66B | $16.37B | $17.41B | −3.5% | 13 |
| Next fiscal year (2027) | $17.22B | $16.65B | $17.58B | +3.4% | 13 |
TEVA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TEVA revenue: reported and forecast
TEVA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | $0.73 | $0.73 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $2.94 | $2.14 | $2.11 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $3.12 | $3.09 | $3.08 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TEVA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TEVA beat in 10 of 12.
What analysts expect from TEVA
13 analysts cover Teva Pharmaceutical Industries; their consensus rating is strong buy (4.54 on a 1–5 scale, where 5 is a strong buy). The average price target is $47.58, 14.7% above the latest close of $41.50. Analysts expect earnings of $2.11 per share for 2026, −29.5% from a year earlier. For 2027 the average estimate is $3.08 per share on revenue of $17.2 billion. Teva Pharmaceutical Industries beat the EPS estimate in 10 of the last 12 quarters.
Related: TEVA income statement, TEVA key metrics, TEVA chart. See the TEVA stock overview for the latest quote and news.
TEVA forecast FAQ
What is Teva Pharmaceutical Industries's price target?
The average analyst price target for Teva Pharmaceutical Industries is $47.58, 14.7% above the latest close of $41.50.
Is Teva Pharmaceutical Industries a buy, hold or sell?
Of 13 analysts covering Teva Pharmaceutical Industries, 8 rate it a strong buy, 4 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Teva Pharmaceutical Industries's EPS forecast?
Analysts forecast $2.11 per share for 2026 (range $1.91 to $2.94); for 2027 the estimate is $3.08.
What is Teva Pharmaceutical Industries's revenue forecast?
The average revenue estimate for 2026 is $16.7 billion, growth of −3.5%; for 2027 it is $17.2 billion.
When does Teva Pharmaceutical Industries report earnings?
Teva Pharmaceutical Industries is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $0.70.
Does Teva Pharmaceutical Industries usually beat earnings estimates?
Teva Pharmaceutical Industries reported EPS at or above the analyst estimate in 10 of the last 12 quarters.